Article

New Serious Safety Warnings of Targeted Anticancer Agents After Their Initial FDA Approval

2025-01-14

Abstract excerpt

<h4>Background: </h4> New safety concerns of the targeted anticancer agents (TAAs) often emerge in the first few years after their initial regulatory approval. Our aim was to determine whether new serious and potentially fatal adverse drug reactions (ADRs) continue to emerge in updated drug labels of TAAs several years after their initial regulatory approval and whether their emergence can be predicted. <h4>Method...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 2bb5f29c-39a6-51f8-97f3-eedf670db39e
DOI: 10.20944/preprints202501.1047.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

New Serious Safety Warnings of Targeted Anticancer Agents After Their Initial FDA ApprovalDOI 10.20944/preprints202501.1047.v1Read

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for TivozanibSemantic proximity Read

Adverse drug reactions associated with the use of biological agentsSemantic proximity Read

A Real-World Disproportionality Analysis of Two Typical First-Generation TRK Inhibitors: Findings from the FDA Adverse Event Reporting System DatabaseSemantic proximity Read

Real-World Data Analysis of Vascular and Lymphatic Adverse Events Associated with Anti-Tumor Angiogenesis Drugs: A WHO-VigiAccess StudySemantic proximity Read

Common Causes and Characteristics of Adverse Drug Reactions in Older Adults: A Retrospective StudySemantic proximity Read

Cutaneous adverse events associated with Rybrevant based on FDA Adverse Event Reporting System (FAERS) database from 2021 to 2024Semantic proximity Read

Pharmacovigilance study of BCR-ABL1 tyrosine kinase inhibitors: A safety analysis of the FDA Adverse Event Reporting SystemSemantic proximity Read

Distinct Adverse Event Profiles of Eight Chemotherapeutic Agents: A FAERS Database Analysis Focusing on Peripheral NeuropathySemantic proximity Read

U.S. Food and Drug Administration utilization of postmarketing requirements and postmarketing commitments, 2009-2018Semantic proximity Read

Safety assessment of S-1: Real-world adverse event analysis from the FAERS databaseSemantic proximity Read

Real-world pharmacovigilance analysis unveils the toxicity profile of amivantamab targeting EGFR exon 20 insertion mutations in non-small cell lung cancerSemantic proximity Read

Reported Drug Spectrum and Disproportionality Signals for Malignant Neoplasm Progression in FAERS: A Real-World Pharmacovigilance StudySemantic proximity Read